Glaxosmithkline Pharmaceuticals Ltd News

GSK Pharma hits 3-month high in weak market; surges 31% in 7 days

GSK Pharma share price: The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December quarter

GlaxoSmithKline hits 20% upper circuit on posting 400% jump in Q3 PAT

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago

GlaxoSmithKline Pharma Q3FY25: Net profit rises 400% to Rs 228.58 crore

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024. The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement. "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added. The company saw strong performance across key product portfolios during the quarter, the drug firm said. Flagship brands within the genera

PVR Inox, Lodha, Glaxo: Should you buy these 5 oversold stocks? Find out

PVR Inox, Lodha, Glaxo, MRF and Astral are trading in oversold zone. Technical charts show these stocks can gain up to 33% from present level, or fall by another 19%; here's why.

GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday's intraday trade

GlaxoSmithKline Pharma Q2 results: Net profit rises 16% to Rs 252 cr

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments. The drug maker posted a net profit of Rs 217 crore for the July-September quarter of last fiscal. Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. The company said its board declared a special interim dividend of Rs 12 per equity share of face value of Rs 10 each. "As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders. Our performance reflects our commitment to sustainable growth and innovation," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The drugmaker said its key brands held their market share and continued to stay in line with the respective category performance. Augmentin ..